These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34667755)

  • 21. High Index Values of Enzyme-Linked Immunosorbent Assay for BP180 at Baseline Predict Relapse in Patients With Bullous Pemphigoid.
    Koga H; Teye K; Ishii N; Ohata C; Nakama T
    Front Med (Lausanne); 2018; 5():139. PubMed ID: 29868591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
    van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
    JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochip technology for the serological diagnosis of bullous pemphigoid.
    Zarian H; Saponeri A; Michelotto A; Zattra E; Belloni-Fortina A; Alaibac M
    ISRN Dermatol; 2012; 2012():237802. PubMed ID: 23346412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid.
    Patsatsi A; Kyriakou A; Pavlitou-Tsiontsi A; Giannakou A; Sotiriadis D
    Clin Dev Immunol; 2012; 2012():854795. PubMed ID: 23227089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid.
    Yoshida M; Hamada T; Amagai M; Hashimoto K; Uehara R; Yamaguchi K; Imamura K; Okamoto E; Yasumoto S; Hashimoto T
    J Dermatol Sci; 2006 Jan; 41(1):21-30. PubMed ID: 16364599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
    Hayakawa T; Teye K; Hachiya T; Uehara R; Hashiguchi M; Kawakami T; Li X; Tsuchisaka A; Ohara K; Sogame R; Koga H; Hamada T; Ohata C; Furumura M; Ishii N; Fukano H; Shimozato K; Hashimoto T
    Eur J Dermatol; 2016 Apr; 26(2):155-63. PubMed ID: 27087683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
    Mai Y; Nishie W; Izumi K; Shimizu H
    Front Immunol; 2019; 10():1224. PubMed ID: 31191560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of autoantibodies against BP180/BP230 in response to topical corticosteroids in patients with bullous pemphigoid.
    Schneiderbauer R; Martinache S; Engstner M; Enk AH; Hadaschik EN
    Dermatol Ther; 2016 Nov; 29(6):419-423. PubMed ID: 27550573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses.
    Feliciani C; Caldarola G; Kneisel A; Podstawa E; Pfütze M; Pfützner W; Hertl M
    Br J Dermatol; 2009 Aug; 161(2):306-12. PubMed ID: 19485996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP.
    Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E
    J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

  • 32. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.
    Schmidt E; Obe K; Bröcker EB; Zillikens D
    Arch Dermatol; 2000 Feb; 136(2):174-8. PubMed ID: 10677092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.
    Fichel F; Barbe C; Joly P; Bedane C; Vabres P; Truchetet F; Aubin F; Michel C; Jegou J; Grange F; Antonicelli F; Bernard P
    JAMA Dermatol; 2014 Jan; 150(1):25-33. PubMed ID: 24226428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
    Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
    Front Immunol; 2021; 12():569287. PubMed ID: 33841390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the autoimmune response against BP180 and BP230 in ethnic Poles with neurodegenerative disorders and bullous pemphigoid.
    Gornowicz-Porowska J; Seraszek-Jaros A; Bowszyc-Dmochowska M; Kaczmarek E; Pietkiewicz P; Bartkiewicz P; Dmochowski M
    Cent Eur J Immunol; 2017; 42(1):85-90. PubMed ID: 28680335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
    Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
    Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice.
    Feldrihan V; Licarete E; Florea F; Cristea V; Popescu O; Sitaru C; Chiriac MT
    Hum Immunol; 2014 Apr; 75(4):354-63. PubMed ID: 24468586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
    Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
    JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.
    Meijer JM; Diercks GFH; de Lang EWG; Pas HH; Jonkman MF
    JAMA Dermatol; 2019 Feb; 155(2):158-165. PubMed ID: 30624575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Place of human amniotic membrane immunoblotting in the diagnosis of autoimmune bullous dermatoses.
    Grootenboer-Mignot S; Descamps V; Picard-Dahan C; Nicaise-Roland P; Prost-Squarcioni C; Leroux-Villet C; Champagnat C; Delaval A; Aucouturier F; Crickx B; Chollet-Martin S
    Br J Dermatol; 2010 Apr; 162(4):743-50. PubMed ID: 19886889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.